134 related articles for article (PubMed ID: 31045869)
1. Association of Hepatic Nuclear Factor 4 Alpha Gene Polymorphisms With Free Imatinib Plasma Levels and Adverse Reactions in Chinese Gastrointestinal Stromal Tumor Patients.
Chen H; Liu J; Zhou Y; Hou Y; Ma G; Cai W
Ther Drug Monit; 2019 Oct; 41(5):582-590. PubMed ID: 31045869
[TBL] [Abstract][Full Text] [Related]
2. Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.
Liu J; Chen Z; Chen H; Hou Y; Lu W; He J; Tong H; Zhou Y; Cai W
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335376
[TBL] [Abstract][Full Text] [Related]
3. [Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors].
Qiu H; Zhuang W; Wang X; Huang M; Zhou Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1031-1034. PubMed ID: 28900995
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
5. Association of Imatinib Plasma Concentration and Single-nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors.
Zhang Q; Xu J; Qian Y; Chen L; Li Q; Xu K; Chen M; Sun L; He Z; Yang L; Zhang D; Wang L; Sun X; Wang Y; Xu H; Xu Z
Mol Cancer Ther; 2018 Dec; 17(12):2780-2787. PubMed ID: 30282814
[TBL] [Abstract][Full Text] [Related]
6. [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].
Yang LX; Wang M; Xu RH; Tu L; Zhuang C; Zhao WY; Ma XL; Li M; Zhang J; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):841-847. PubMed ID: 31550823
[No Abstract] [Full Text] [Related]
7. Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors.
Maekawa K; Yamamura M; Matsuki A; Ishikawa T; Hirai T; Yamaguchi Y; Saito Y; Kanda T
Drug Metab Pharmacokinet; 2022 Apr; 43():100441. PubMed ID: 35144161
[TBL] [Abstract][Full Text] [Related]
8. Genetic variations of NR2A1 in Asian populations: implications in pharmacogenetics studies.
Chew SC; Lim JS; Lee EJ; Chowbay B
Drug Metab Pharmacokinet; 2013; 28(3):278-88. PubMed ID: 23268925
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
[TBL] [Abstract][Full Text] [Related]
10. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
[TBL] [Abstract][Full Text] [Related]
11. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors.
Xia Y; Chen S; Luo M; Wu J; Cai S; He Y; Chen X; Zhang X
Cancer; 2020 May; 126 Suppl 9():2054-2061. PubMed ID: 32293723
[TBL] [Abstract][Full Text] [Related]
12. Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.
Teranishi R; Takahashi T; Nishida T; Kurokawa Y; Nakajima K; Koh M; Nishigaki T; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Motoori M; Omori T; Hirota S; Hayashi Y; Takehara T; Eguchi H; Doki Y
Int J Clin Oncol; 2023 May; 28(5):680-687. PubMed ID: 36971916
[TBL] [Abstract][Full Text] [Related]
13. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
Zhuang W; Xie JD; Zhou S; Zhou ZW; Zhou Y; Sun XW; Yuan XH; Huang M; Liu S; Xin S; Su QB; Qiu HB; Wang XD
Cancer Med; 2018 Feb; 7(2):317-324. PubMed ID: 29316372
[TBL] [Abstract][Full Text] [Related]
14. Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor.
Wu X; Li J; Zhou Y; Mao Y; Luo S; He X; Wang L; Shen Y; Zhang H; Yang L; Zhang J
Chemotherapy; 2018; 63(6):301-307. PubMed ID: 30836365
[TBL] [Abstract][Full Text] [Related]
15. [A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration].
Xu H; Ma L; Xu W; Guan W; Wang B; Li G; Miao Y; Li L; Chen H; Yu J; Wang Y; Sun L; Yang L; Zhang D; Li F; Zhi X; Wang J; Xu J; Xu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1271-1276. PubMed ID: 27928798
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between N-Demethyl Imatinib Trough Concentration and Serious Adverse Reactions in Patients with Gastrointestinal Stromal Tumors: A Retrospective Cohort Study.
Liu M; Guo T; Ma Z; Du L; Hou J; Tian Y; Meng M; Chen X
Ther Drug Monit; 2024 Jun; 46(3):344-350. PubMed ID: 38176855
[TBL] [Abstract][Full Text] [Related]
17. A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients.
Zeng L; Cheng X; Li J; Zhang J; Wu X
PLoS One; 2024; 19(5):e0303290. PubMed ID: 38743680
[TBL] [Abstract][Full Text] [Related]
18. Contribution of genetic polymorphism in
Ge Y; Bai H; Mazzocca A; Zhang J; Wang Z; Wu X
J Gastrointest Oncol; 2024 Apr; 15(2):577-584. PubMed ID: 38756645
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
Takahashi N; Miura M; Scott SA; Kagaya H; Kameoka Y; Tagawa H; Saitoh H; Fujishima N; Yoshioka T; Hirokawa M; Sawada K
J Hum Genet; 2010 Nov; 55(11):731-7. PubMed ID: 20720558
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients.
Dalle Fratte C; Gagno S; Roncato R; Polesel J; Zanchetta M; Buzzo M; Posocco B; De Mattia E; Borsatti R; Puglisi F; Foltran L; Guardascione M; Buonadonna A; Cecchin E; Toffoli G
Br J Clin Pharmacol; 2023 Mar; 89(3):1089-1098. PubMed ID: 36178950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
